Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-138.43M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.09 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -197.71% |
| Return on Assets (Trailing 12 Months) | -134.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.25 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.25 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.42 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.80 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.55 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 37.57M |
| Free Float | 30.65M |
| Market Capitalization | $88.67M |
| Average Volume (Last 20 Days) | 4.42M |
| Beta (Past 60 Months) | -0.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.42% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |